Treatment seeks approval
New rickets drug ‘milestone’ for Borders firm
Now named Kyowa Kirin International (KKI) the Galashiels business describes the development of KRN23 as a major milestone for the company.
Its parent company Kyowa Hakko Kirin signed a collaboration and licence deal with US-based Ultragenyx Pharmaceutical on the new treatment for a rare form of rickets, known as X-linked hypophosphatemia.
An opinion from the Committee for Medicinal Products for Human Use is expected in the second half of this year.
Emil D Kakkis, chief executive and president of Ultragenyx, said: “Based on the positive results from multiple studies in paediatric and adult patients with XLH, we are pursuing conditional marketing authorisation in order to accelerate access to this therapy for patients.
Dr Tom Stratford, president and CEO of KKI, said: “X-linked hypophosphatemia is a debilitating condition which causes long term pain and distress among sufferers and for which there are no currently approved treatments that target the underlying cause.
“As part of Kyowa Hakko Kirin, we strive to contribute to the health and wellbeing of people around the world through advances in life sciences and technologies.”